APiX chromogenic technology allows for the detection of any biotinylated molecule, generating light grey-to-black spots that are visible to the naked eye and can be scanned with the Gentel Proteomics Multi-System.

APiX is also compatible with a variety of secondary antibodies such as anti-mouse and anti-rabbit. APiX uses a proprietary gold-catalyzed silver deposition and typically achieves measurably improved sensitivity compared to fluorescence detection.

Tumor lysates arrays are a type of reverse phase protein microarray that contains a collection of up to several hundred tumor samples on slide. Antibodies or other probes are applied to the array to detect the abundance of specific protein biomarkers and measure expression across a large population of tumor samples. Array results are then compared to demographic and relevant clinical disease-specific data on the tumor collection to draw a conclusion.

APiX View detection reagents are compatible with the Gentel Proteomics Multi-System, which provides ‘scan-to-analysis’ functionality for multiplex immunoassays, tumor lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging.

Alex Vodenlich, president and CEO of Gentel, said: “This launch expands the applications of APiX technology to include not only antibody and protein arrays on clear glass slides, but also tumor lysate arrays on porous nitrocellulose surfaces. Now virtually any commercial protein microarray can take advantage of Gentel’s chromogenic detection.”

Phillip Schwartz, president and CEO of Protein Biotechnologies, has recognized the potential of the Gentel reagents and system for use with Protein Biotechnologies’ SomaPlex tumor lysate arrays.

He said: “Our customers are looking for a simple, sensitive, and affordable detection method for use with SomaPlex arrays. The Gentel Proteomics Multi-System meets this need.

“We are excited about how Gentel’s easy-to-use kits and affordable system can help make arrays accessible to whole a new group of users.”